Drug
Odevixibat clinical trials
Also written A4250.
- studies test it
- 10
- open now
- 0
- in phase 3
- 6
- first study started
- 2013
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 2 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Albireo (5) · Albireo, an Ipsen Company (4) · Sahlgrenska University Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses odevixibat is read from its arms, and is right about nine times in ten.
Testing it · 10
- Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeActive, not recruitingPhase 3Albireo, an Ipsen CompanyNCT05035030Written as Odevixibat
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaActive, not recruitingPhase 3Albireo, an Ipsen CompanyNCT05426733Written as Odevixibat
- Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFICCompletedPhase 3Albireo, an Ipsen CompanyNCT03659916Written as A4250 (odevixibat)
- Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)CompletedPhase 3Albireo, an Ipsen CompanyNCT04336722Written as Odevixibat
- This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2CompletedPhase 3AlbireoNCT03566238Written as A4250 (odevixibat)
- A4250, an IBAT Inhibitor in Pediatric CholestasisCompletedPhase 2AlbireoNCT02630875Written as A4250
- Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled ConditionsCompletedPhase 1AlbireoNCT03608319Written as A4250
- A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384CompletedPhase 1AlbireoNCT02963077Written as A4250
- Efficacy and Safety of Odevixibat in Patients With Alagille SyndromeCompletedPhase 3AlbireoNCT04674761Written as Odevixibat
- IBAT Inhibitor A4250 for Cholestatic PruritusTerminatedPhase 2Sahlgrenska University HospitalNCT02360852Written as A4250
Codes
What other systems call odevixibat · ClinicalTrials.gg INT001543
- MeSH (NLM) C000713258odevixibatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2W150K0UUCODEVIXIBATConfirmed FDA, NLM, Wikidata
- RxNorm 2563966One source FDA
- Wikidata Q76415200odevixibatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166598OdevixibatOne source FDA
- DrugBank DB16261One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000713258 | odevixibat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2W150K0UUC | ODEVIXIBAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2563966 | — | One source FDA |
| Wikidata | Q76415200 | odevixibat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166598 | Odevixibat | One source FDA |
| DrugBank | DB16261 | — | One source Wikidata |
Also registered as odevixibat sesquihydrate (UNII Q76KP2H4XW · RxNorm 2563978).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.